Últimas noticias sobre Bone Biologics (NASDAQ:BBLG) Bolsa

Bone Biologics

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Bone Biologics Corp

CETX

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

UPXI

The head-to-head battle between Donald Trump and Vice President Kamala Harris could come down to seven key swing states for the winner of the <a href="https://www.benzinga.com/topic/2024-election">2024 presidential election.</a>
New election polls show Harris might be in trouble in several key swing states.
What Happened: While most election polls <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40993290/trump-vs-harris-2024-election-betting-odds-show-vice-president-maintains-lead-as-race-near">and betting odds</a> show Harris with a lead over Trump, swing state polls may paint a different picture.
New swing state polls from Emerson College show Harris trailing or tied with Trump in key battleground territories.
In a <a href="https://emersoncollegepolling.com/september-2024-pennsylvania-poll-trump-48-harris-48/">poll </a>of Pennsylvania voters, Trump and Harris are tied at 48% each. One of the sticking factors could be the economy with 51% of voters saying they believe Trump is the better candidate for their personal financial situation, compared to 44% who picked Harris.
In the poll, the economy was listed as the top issue for the 2024 election at 50%. Sixty percent of voters said they believe their economic situation is worse today than five years ago.
In a <a href="https://emersoncollegepolling.com/september-2024-arizona-and-north-carolina-polls-harris-and-trump-neck-and-neck-in-key-swing-states/">poll </a>of Arizona voters, Trump leads with 50% of the vote with Harris having 47% of the vote.
Similar to other states, the economy is the top issue for Arizona voters. Of those polled, 53% said they believe Trump will be better for their personal finances.
In a poll of North Carolina voters, Trump leads with 49% of the vote with Harris having 48% of the vote.
In North Carolina, the economy is the top voter issue for the 2024 election. Fifty-one percent of voters said they believe Trump would be better for their personal finances.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100224">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Arizona, North Carolina and Pennsylvania are three of the key<a href="https://www.benzinga.com/topic/swing-states"> seven swing states </a>that could decide the 2024 presidential election and have 11, 16 and 19 electoral college votes, respectively.
With the other four swing states of Georgia, Michigan, Nevada and Wisconsin, the seven states represent 93 electoral college votes.
The state of Arizona voted Democrat in 2020. The only other time it did so was in 1996 with Bill Clinton winning — ending the streak of the state voting for the Republican candidate since 1952.
The state of North Carolina voted for a Republican candidate in the past three presidential elections. In 10 of the past 12 elections, the state has voted for a Republican presidential candidate.
Pennsylvania could prove to be a troublesome state for Harris based on the latest poll that shows she is tied with Trump. Pennsylvania voted for a Democrat in 2020 after flipping the state back from a Republican in 2016. In seven of the past eight elections and eight of the past 12, Pennsylvania has voted for a Democrat candidate for president. (The Republican candidate won in 1980, 1984 and 1988.)
President Joe Biden won the 2020 election as he was able to flip several swing states from red to blue. Harris will need to hold onto several of the key swing states to win the 2024 election. The latest poll shows that Trump may be in a good position to once again become president of the U.S.
Check This Out:
<ul>
<li>Lawmakers Made Huge Investments This Year. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100224">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Photo: Gguy via Shutterstock

Politics

Harris In Trouble: Vice President Trails Trump In Two Key Swing States, Tied In State That Has Voted For A Democrat 7 Of Last 8 Elections

IMRN

Trading Halt: Halted at 7:05:25 p.m. ET - Trading Halt: Halt News Pending

Ohio's recreational marijuana industry is gaining momentum, with sales reaching $76.3 million as of the end of September. When recreational cannabis shops <a href="https://www.benzinga.com/markets/cannabis/24/08/40172821/its-official-ohio-begins-recreational-cannabis-sales-on-tuesday-heres-where-and-how-you-know-the">officially opened their doors </a>this past Aug. 6, sales <a href="https://www.benzinga.com/markets/cannabis/24/08/40492614/smoke-much-weed-ohio-38-5m-in-first-two-weeks-of-adult-use-sales-including-medical-marijuana">zoomed to over $22.5 million</a> in the first 12 days with medical marijuana contributing an additional $16 million.
In under two months, Ohio's legal weed market has moved over 8,813 pounds of plant materials and 1.2 million units of manufactured products through the state's 124 dual-use dispensaries that cater to both medical and recreational customers.
<h1 class="wp-block-heading">Neighboring Michigan: A Well-Established Competitor</h1>
Though Ohio's market is moving right along after last <a href="https://www.benzinga.com/markets/cannabis/23/11/35664155/ohio-legalizes-cannabis-and-overwhelmingly-approves-abortion-rights">November's legalization vote</a>, Michigan's industry is chugging ahead even faster. Recreational marijuana sales, which began there in 2019 have continued to rise despite Ohio's legalization. In August, for example, Michigan's total cannabis sales <a href="https://www.benzinga.com/markets/cannabis/24/09/40831750/cannabis-sales-in-michigan-soar-to-295-4m-for-a-recording-breaking-august">hit a record-breaking $295.4 million</a> essentially indicating that weed vendors are retaining customers despite new competition from Ohio.
Why? "Frankly, it is still worth it for me to drive to Michigan to buy cannabis," one Ohioan from a Cleveland suburb told Benzinga. "Marijuana prices here [in Ohio] are still much higher than in Michigan. So it&#8217;s cheaper even after I pay for gas to drive both ways. "
Zach Gergich, a representative from Nectar, a dispensary in the college town of Bowling Green, Ohio, expressed optimism about Ohio's potential.
"We're five-to-10 times busier here depending on the day," Gergich <a href="https://www.13abc.com/2024/09/25/recreational-marijuana-sales-increasing-michigan-ohio/">told</a> 23ABC. "We've been crushing it up here."
Sales numbers, however, show that Ohio weed shops are not exactly crushing their competitors on the other side of the state line.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40742561/ohios-cannabis-sales-reach-44m-as-new-customers-just-keep-coming-and-demand-is-not-slowing">Ohio&#8217;s Cannabis Sales Reach $44M As New Customers Just Keep Coming And Demand Is Not Slowing</a>
<h1 class="wp-block-heading">Plenty Of Weed Money To Go Around In Both States</h1>
While Ohio's fledgling market is showing promise, Michigan's resilience suggests it won't be easy for the Buckeye State to overtake its northern neighbor anytime soon. Although for now, both states seem to have plenty of demand to meet.
"I think it's only going to get more competitive. We'll see, you know, more licenses pop up for growers and processors and stuff like that," Gergich said. "So obviously more there, more of them, you know, prices should start we hopefully should see them fall a little bit and kind of get more competitive in that range."
Now Read: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41149545/trump-harris-vance-and-walz-agree-on-this-end-cannabis-criminalization-in-florida">Trump, Harris, Vance And Walz Agree On This: End Cannabis Criminalization In Florida</a></li>
</ul>

This image was created using artificial intelligence.

Cannabis

News

Retail Sales

Ohio Cannabis Market Soars To $76M In Less Than 2 Months But Michigan Remains The Leader

The Application was submitted on July 19, 2024, and passed the initial FDA Administrative Review. The FDA informed the Company that the FDA placed the Application on hold pending a complete response to the AIR.
The FDA has informed the Company that the Company has 180 days from the date of the AIR to provide a complete response to the AIR or the FDA will consider the Application withdrawn.
As the Company works to respond to the AIR, the Company, in parallel, will pursue a submission for its active modality with Outside the United States (&quot;OUS&quot;) clinical data as it continues to work through the AIR for its semi-active system.

MGRM

Monogram Technologies Receives Additional Information Request From FDA On September 30, 2024, Regarding Its 510(K) Premarket Filing Submission For mBôs TKA System

B of A Securities analyst Kevin Fischbeck downgrades Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) from Neutral to Underperform and lowers the price target from $376 to $247.

Downgrades

Price Target

Analyst Ratings

B of A Securities Downgrades Humana to Underperform, Lowers Price Target to $247

UMH Properties Expects Effects Of Hurricane Helene Storm Not To Have Material Impact On Its Operations Or Financial Results

As the curtain rises on the iPhone 16 Series, Apple enthusiasts are buzzing with anticipation. However, JPMorgan analyst Samik Chatterjee suggests that while the hype is palpable, the initial momentum for high-end models appears muted compared <a href="https://www.benzinga.com/quote/AAPL/news">to past launches</a>. 
<h2 class="wp-block-heading">iPhone 16: &#8216;Launch Lacking Early Momentum&#8217;</h2>
Chatterjee highlights that the rollout has faced a slight hiccup, primarily due to the unavailability of AI capabilities, which seems to be causing a pause among potential buyers.
In Chatterjee&#8217;s latest insights, he points out, "Early signs are indicating a robust product cycle; albeit, with the launch lacking early momentum for the high-end models." This may prompt consumers to hold off on their purchases until they can fully grasp the AI value proposition. 
As a result, JPMorgan has adjusted its near-term iPhone unit forecast, now estimating about 126 million iPhones sold in the second half of 2024, down from 130 million previously.
Read Also: <a href="https://www.benzinga.com/news/24/10/41146507/apples-iphone-16-series-leads-growth-but-high-end-model-preference-declines-analyst">Apple&#8217;s iPhone 16 Series Leads Growth, But High-End Model Preference Declines: Analyst</a>
<h2 class="wp-block-heading">Medium-Term Prospects Are Bullish, Says Apple Analyst</h2>
Despite these short-term adjustments, Chatterjee maintains a bullish outlook on the medium-term prospects for Apple. He asserts, "We continue to forecast aggregate volumes for the 16 Series over the next four quarters to track ahead of both the 15 and 14 Series," indicating a confidence that consumer appetite for AI-integrated features will ramp up once they become widely available.
<h2 class="wp-block-heading">Long-Term Upside Is Evident</h2>
The analyst's enthusiasm for the long-term potential is underpinned by expectations of a robust AI upgrade cycle. "We see upside in several aspects of the business&#8230; transformation of the company to Services, growth in the installed base, technology leadership, and optionality around capital deployment," he said
With this optimism, JPMorgan reiterates its price target for Apple at $265 by December 2025.
Investors might feel a pinch in the near term, as the excitement around AI upgrades may not translate into immediate sales.
But, as Chatterjee aptly puts it, "The slower start to the AI cycle than originally anticipated" is just a temporary roadblock to growth. The real treasure, he believes, lies just beyond the horizon as Apple continues to evolve and innovate.
While the iPhone 16 Series may not be breaking records just yet, the groundwork for a significant AI upgrade cycle is being laid, promising a future where Apple once again dazzles its fans and investors alike.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/10/41141152/cramer-says-hot-money-flowing-from-nvidia-apple-into-china-focus-on-alibaba-if-you-must">Cramer Says &#8216;Hot Money&#8217; Flowing From Nvidia, Apple Into China, Focus On Alibaba &#8216;If You Must&#8217;</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Long Ideas

Tech

Trading Ideas

AAPL

Apple Analyst Signals 'Slower Start To The AI Cycle' As iPhone 16 Demand Softens

Consumer Reports recently reviewed the Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) Cybertruck and shared its likes and dislikes about the electric pickup truck that began consumer deliveries <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/11/36032944/cybertruck-delivery-event-elon-musk-highlights-teslas-best-product-says-finally-the">in November 2023.</a>
What Happened: Known for its unique design, the Cybertruck has<a href="https://www.benzinga.com/general/entertainment/24/03/37852639/tesla-cybertruck-the-new-celebrity-fashion-accessory-steve-aoki-big-sean-latest-to-own-ev"> attracted demand from celebrities</a> and fans of Tesla vehicles and CEO Elon Musk.
The vehicle has also sold well compared to other electric pickup trucks on the market, even though it has a higher price point than some.
In its review <a href="https://www.youtube.com/watch?v=Q49hsOZKKxU" target="_blank" rel="noopener">video</a>, Consumer Reports reviewer Alex Knizek points to steering as one of the features he liked the least about the Cybertruck. Knizek also said he disliked engaging the turn signal, which removed the rearview camera and replaced it with a blind spot camera.
The reviewer said one of his favorite parts is the giant windshield wiper. Knizek also highlighted that driving the Cybertruck was met with peace signs and thumbs up from nearby people, and the vehicle generated strong reactions that were mostly positive.
The Cybertruck&#8217;s review on the Consumer Reports <a href="https://www.consumerreports.org/cars/tesla/cybertruck/2024/road-test-report/#pagestop" target="_blank" rel="noopener">website </a>includes sections on power and braking, ride and handling, front visibility, comfort, and bed storage.
Speaking of the six-foot bed in the review video, Knizek said the Cybertruck is "even a pretty decent pickup truck."
The website review highlights several drawbacks of the Cybertruck, including limited visibility aside from the front, steering issues, camera performance, difficulty with cleaning, challenges in the delivery process, the price point, and the "usual Tesla shenanigans."
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent100224">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Most of the Cybertruck reviews to date have come from Tesla fans and influencers who waited a long time to get their hands on the vehicle. Many of these reviewers may already be fans of Tesla vehicles and slightly biased.
Consumer Reports is well-known for its reviews, and its mixed reviews of the Cybertruck may come off as positive for the Tesla electric pickup truck.
The review highlighted several features,, including Tesla&#8217;s technological advancements and how the Cybertruck still holds its own as a pickup truck despite what some consider a look that is anything but a truck.
TSLA Price Action: Tesla shares were down 3.4% to $249.02 on Wednesday, versus a 52-week trading range of $138.80 to $271.00. Tesla stock is trading nearly flat year-to-date in 2024.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41145803/tesla-q3-deliveries-step-in-the-right-direction-analyst-says-more-heavy-lifting-nee">Tesla Q3 Deliveries &#8216;Step In The Right Direction&#8217;: Analyst Says More &#8216;Heavy Lifting&#8217; Needed From Elon Musk To Turn Growth Story Around</a></li>
</ul>
Photo courtesy of Tesla.

TSLA

Tesla Cybertruck Is 'Pretty Decent Pickup Truck': Consumer Reports Review

Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) has outperformed the market over the past 10 years by 3.94% on an annualized basis producing an average annual return of 15.34%. Currently, Ciena has a market capitalization of $9.48 billion. 
Buying $1000 In CIEN: If an investor had bought $1000 of CIEN stock 10 years ago, it would be worth $4,062.77 today based on a price of $66.00 for CIEN at the time of writing.
<h3>Ciena's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727905022_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CIEN

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,100 Today

Accenture Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) shares moved higher Wednesday after the company announced it expanded its partnership with NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) to launch the <a href="https://www.benzinga.com/markets/equities/24/10/41142895/accenture-and-nvidia-team-up-to-supercharge-global-ai-adoption-details">Accenture NVIDIA Business Group. </a>
The Details: Accenture said the new Accenture Nvidia Business Group launched with 30,000 professionals receiving <a href="https://www.benzinga.com/pressreleases/24/10/b41138752/accenture-and-nvidia-lead-enterprises-into-era-of-ai">training globally</a> to help clients scale enterprise AI adoption with AI agents using Accenture&#8217;s AI Refinery developed on the NVIDIA AI stack.&nbsp;
The Accenture AI Refinery will be available on all public and private cloud platforms and will integrate with other Accenture Business Groups to accelerate AI across the SaaS and Cloud AI ecosystem.
Read Next: <a href="https://www.benzinga.com/news/24/10/41129365/what-happened-with-rivian-stock-today">What Happened With Rivian Stock Today?</a>
Wedbush tech analyst Dan Ives <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41151741/nvidias-ai-leadership-to-drive-1-trillion-market-growth-with-accenture-partnership-">cheered the new venture</a>, describing it as &#8220;the tip of the iceberg on the broader AI Revolution and demand adoption into 2025 and beyond.&#8221;
Ives also mentioned both companies <a href="https://x.com/DivesTech/status/1841495758047952990">in a post </a>on the social media platform X in which he described the partnership as the "AI Revolution taking hold."&nbsp;
Accenture shares are moving higher in Wednesday's extended trading after its CEO Julie Sweet and Nvidia CEO Jensen Huang appeared together on CNBC's Closing Bell Overtime program.&nbsp;
ACN Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Accenture shares are up 2.15% after-hours at $363.96 after climbing 1.20% in Wednesday's regular trading session.&nbsp;
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41122476/whats-going-on-with-microstrategy-stock">What&#8217;s Going On With MicroStrategy Stock?</a></li>
</ul>
Photo: Courtesy of Accenture Plc

After-Hours Center

Movers

NVDA

What Happened With Accenture Stock Today?

There was no serious damage to equipment and both facilities are resuming operations.

Clearwater Paper Says It Temporarily Suspended Operations At Its Augusta, Georgia Paperboard Facility And Its Shelby, North Carolina Tissue Facility Due To Impacts From Hurricane Helene

Today, the Company issued 46.349 million shares of its Class A common stock at a public offering price of&nbsp;$8.63&nbsp;per share, for a total offering of&nbsp;$400 million.
Wes Edens, Chairman and CEO of New Fortress Energy, purchased 5.79 million shares, totaling ~$50 million&nbsp;of the offering, at the public offering price.
Additionally, on October 1, 2024, the Company entered into a Transaction Support Agreement with certain of its existing noteholders.

Offerings

New Fortress Energy Reveals Two Transformative Debt And Equity Transactions Totaling Approximately $3B Upon Completion

Novagold Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NG#AMEX">NG</a>) reported quarterly losses of $(0.03) per share. This is unchanged from the same period last year.

Earnings

Novagold Resources Q3 2024 GAAP EPS $(0.03), Same YoY

As Rockstar Games&#8216; next installment in the Grand Theft Auto series gets closer to its anticipated release window, excitement around the title is as high as it&#8217;s ever been — <a href="https://www.benzinga.com/general/entertainment/24/06/39555552/rockstar-games-co-founder-reveals-why-gta-movie-never-made-sense">for most</a>.
What To Know: Fans of the series appear to have gotten another sneak peek at what&#8217;s coming in Grand Theft Auto VI (GTA 6).
According to a GamingBible<a href="https://www.gamingbible.com/news/gta-6-leaked-gameplay-screenshot-033212-20241002"> report</a>, X account &#8220;GTA 6 Countdown&#8221; recently shared a series of leaks, including an AI-generated image that sent fans into a frenzy.
Rockstar Games has a long history of leaks, so the latest reveal shouldn&#8217;t come as a surprise. But this particular leak is getting a lot of attention: Rockstar Games parent company Take-Two Interactive Software Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) sent a Digital Millennium Copyright Act notice to the X creator on Tuesday, forcing the user to take down the image.
Several GTA 6 fans speculated that the image might have been an actual screenshot of the gameplay given Take-Two&#8217;s response to the post before one X user noticed it was an enhanced version of an earlier gameplay screenshot released in 2022.
Another fan suggested that the image was a concept created with <a href="http://benzinga.com/topic/ai">AI</a> and that Take-Two&#8217;s system likely mistook the image for a leaked screenshot.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">This leak has been pretty much confirmed, as we just received a DMCA takedown from Rockstar's parent company, Take-Two. <a href="https://t.co/sxrlKzPT0w">https://t.co/sxrlKzPT0w</a>
&mdash; GTA 6 Countdown &#x23f3; (@GTAVI_Countdown) <a href="https://twitter.com/GTAVI_Countdown/status/1841041117548011826?ref_src=twsrc%5Etfw">October 1, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
All of the excitement surrounding potential leaks comes as Rockstar Games gears up to release the second trailer for GTA 6 on Oct. 4. 
The game itself is expected to be released in the fall of 2025, as announced in the<a href="https://www.benzinga.com/general/gaming/23/12/36119465/gta-6-trailer-breaks-records-surpasses-108-million-views-in-less-than-48-hours-outshining-predeces"> first trailer</a> for the highly-anticipated game. 
The original trailer set a 24-hour viewership record for YouTube video game reveals and had more than 100 million views within 48 hours. Interestingly enough, the first trailer leaked a day ahead of its planned release.
See Also:<a href="https://www.benzinga.com/general/gaming/24/10/41127513/final-fantasy-16-on-xbox-square-enix-hints-at-a-possible-release"> Final Fantasy 16 On Xbox? Square Enix Hints At A Possible Release</a>
GTA 6 may very well be the most anticipated video game release of all time, but not for X owner Elon Musk.
In an X post from late 2023 shortly after the first GTA 6 trailer was released, Musk noted that he once tried to play the game, but &#8220;didn&#8217;t like doing crime.&#8221;
&#8220;GTA5 required shooting police officers in the opening scene. Just couldn't do it,&#8221; Musk said in the <a href="https://x.com/elonmusk/status/1731894072300699768?lang=en">post</a>.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Tried, but didn't like doing crime. GTA5 required shooting police officers in the opening scene. Just couldn't do it.
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1731894072300699768?ref_src=twsrc%5Etfw">December 5, 2023</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Grand Theft Auto series is known for violence and plot lines focused on organized crime. Rockstar Games has sold more than <a href="https://www.benzinga.com/general/gaming/24/05/38900608/gta-5-surpasses-200-million-copies-sold-only-two-games-have-outsold-it#">200 million copies</a> of Grand Theft Auto V since it was released in 2013. 
Although Musk isn&#8217;t a fan of the game, he&#8217;s no stranger to gaming. The eccentric billionaire <a href="https://www.benzinga.com/general/gaming/23/08/33610477/elon-musk-lover-of-video-games-has-praise-for-this-record-breaking-title-and-its-not-elden-ring">made several posts</a> in 2022 on X, then-Twitter, about popular game&nbsp;Elden Ring. He also praised the creators of Diablo IV last year, calling it a &#8220;great&#8221; game.
Musk has made a push to get more gamers to livestream on X over the past year and recently began sponsoring gamers on the X platform through <a href="https://x.com/XGaming">X Gaming</a>. 
X Gaming made a <a href="https://x.com/XGaming/status/1834412970811728126">post</a> last month highlighting a new deal with some of the world&#8217;s top streamers. 
&#8220;Whatever feedback they have, we will build it,&#8221; X Gaming said. &#8220;More coming soon!&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/09/40905542/could-gta-6-be-pushed-to-2026-insights-from-former-rockstar-insider">Could GTA 6 Be Pushed To 2026? Insights From Former Rockstar Insider</a></li>
</ul>
Image: courtesy of Take-Two Interactive Software.

Gaming

General

TTWO

Grand Theft Auto 6 Leak Sparks Fan Frenzy On X, But Elon Musk Won't Be  Joining The Hype

In addition, Hambly will become a member of the Board of Directors. Jenkins will retire from the Board on December 31, 2024. He will remain with Murphy in a non-executive role as an advisor until his retirement on December 31, 2025.

Management

Murphy Oil Appoints Eric Hambly To Succeed Roger Jenkins As President And CEO, Effective January 1, 2025

Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) reported quarterly losses of $(0.06) per share. This is a 50 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $183.00 thousand which missed the analyst consensus estimate of $200.00 thousand by 8.50 percent.&nbsp;

Earnings Misses

QUBT

Quantum Computing Q2 2024 GAAP EPS $(0.06) Up From $(0.12) YoY, Sales $183.00K Miss $200.00K Estimate

In the last three months, 8 analysts have published ratings on Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>), offering a diverse range of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Avery Dennison and provided 12-month price targets. The average target is $250.82, accompanied by a high estimate of $274.60 and a low estimate of $235.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.02%. 
<img src="https://www.benzinga.com/files/images/story/2024/1727902961_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Avery Dennison among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$240.00</td>
<td>$241.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$252.00</td>
<td>$254.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$235.00</td>
<td>$262.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$254.00</td>
<td>$256.00</td>
</tr>
<tr>
<td>Michael Roxland</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$258.00</td>
<td>$253.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$252.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Lars Kjellberg</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$274.60</td>
<td>-</td>
</tr>
<tr>
<td>Anthony Pettinari</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$241.00</td>
<td>$230.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Avery Dennison. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Avery Dennison compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Avery Dennison's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Avery Dennison's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AVY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Avery Dennison analyst ratings.</a>
<h2>All You Need to Know About Avery Dennison</h2>
Avery Dennison manufactures pressure-sensitive materials, merchandise tags, and labels. The company also runs a specialty converting business that produces radio-frequency identification, or RFID, inlays and labels. Avery Dennison draws a significant amount of revenue from outside the United States, with international operations accounting for the majority of total sales.
<h3>Avery Dennison: Delving into Financials</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Avery Dennison's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 6.93%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Materials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 7.91%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Avery Dennison's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 7.87%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Avery Dennison's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 2.14%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Avery Dennison's debt-to-equity ratio is below the industry average at 1.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 8 Analyst Recommendations For Avery Dennison

Terms of the settlement agreement include cases in both the&nbsp;Rhode Island&nbsp;consolidated litigation and the federal multidistrict litigation in&nbsp;Ohio.&nbsp;
The aggregate amount payable pursuant to this settlement is within the company&#39;s current product litigation reserve for this matter and will be paid out over a multi-year period.
As a result, the settlement amount is already recorded as a liability within BD&#39;s consolidated balance sheet and the agreement will not result in an incremental charge to the company&#39;s consolidated income statement. BD believes this agreement is in the best interest of all parties and is structured to eliminate uncertainty for all stakeholders related to the settled cases. &nbsp;The hernia mass tort litigation represents a large majority of BD&#39;s total product litigation reserve.

Legal

BD Reaches Agreement To Resolve Vast Majority Of Its Existing Hernia Litigation, Terms Confidential; Expects Settlement Not To Change Cash Flow Goals Or Capital Allocation Strategy

Bone Biologics Corp (BBLG) stock has risen 2.99% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Bone Biologics Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BBLG!See Full BBLG ReportWhat is Stock Sentiment?Sentiment is a

Should You Buy Bone Biologics Corp (BBLG) Stock After it Is Up 2.99% in a Week?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) just reported results for the first quarter of 2024.<ul><li>Bone Biologics reported earnings per share of -$1.31. This was above the analyst estimate for EPS of -$7.60.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/bblg-stock-earnings-bone-biologics-for-q1-of-2024/">BBLG Stock Earnings: Bone Biologics Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BBLG Stock Earnings: Bone Biologics Beats EPS for Q1 2024

Novavax, Capricor Therapeutics, Arcutis Biotherapeutics among healthcare movers

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we dive into all of the biggest ones worth watching on Wednesday morning!



Moving stocks are new deals and contracts, earnings reports, stock offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is rocketing more than 821% on a deal to <a href="https://www.nasdaq.com/press-release/actelis-receives-new-orders-supply-three-military-bases-cyber-hardened-networking">supply technology to three military bases</a>.</li>



<li>MF International (NASDAQ:<a href="https://investorplace.com/stock-quotes/mfi-stock-quote/">MFI</a>) shares are soaring over 139% with heavy trading roughly <a href="https://www.marketwatch.com/story/mf-international-shares-more-than-double-in-trading-debut-after-ipo-607bbac5">one month after its public debut</a>.</li>



<li>ENDRA Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ndra-stock-quote/">NDRA</a>) stock is surging more than 63% after falling yesterday on an <a href="https://www.investing.com/news/company-news/endra-life-sciences-sets-8-million-stock-offering-93CH-3470094">$8 million stock offering</a>.</li>



<li>WalkMe (NASDAQ:<a href="https://investorplace.com/stock-quotes/wkme-stock-quote/">WKME</a>) shares are gaining over 43% on a <a href="https://seekingalpha.com/news/4112995-walkme-stock-leaps-after-15b-takeover-deal-with-sap?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">$1.5 billion takeover deal</a>.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) stock is rising more than 33% with strong early morning trading.</li>



<li>Moving iMage Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/mitq-stock-quote/">MITQ</a>) shares are increasing over 25% after being <a href="https://www.nasdaq.com/press-release/moving-image-technologies-mit-awarded-multi-million-dollar-contract-state-art-alamo">granted a new contract</a>.</li>



<li>Jayud Global Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/jyd-stock-quote/">JYD</a>) stock is heading more than 22% higher alongside heavy trading this morning.</li>



<li>U Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucar-stock-quote/">UCAR</a>) shares are climbing over 20% <a href="https://www.nasdaq.com/press-release/uotta-technology-be-adopted-portuguese-national-taxi-association-drive">on a deal</a> with the Portuguese National Taxi Association.</li>



<li>Stitch Fix (NASDAQ:<a href="https://investorplace.com/stock-quotes/sfix-stock-quote/">SFIX</a>) stock is jumping more than 16% after <a href="https://finance.yahoo.com/news/stitch-fix-sfix-reports-q3-212003374.html">beating revenue estimates in fiscal Q3</a>.</li>



<li>Calidi Biotherapeutics (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/">CLDI</a>) shares are up over 14% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318374243&amp;type=PDF&amp;symbol=CLDI&amp;cdn=26f24d99b28a708fa7751a113b343d34&amp;companyName=Calidi+Biotherapeutics+Inc.&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-06-04">warrant exercise agreement</a>.</li>
</ol><h2>10 Top Losers</h2><ol></ol><ol><li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is retreating more than 26% <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-162-today/">following a rally yesterday</a>.</li>



<li>SilverSun Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/ssnt-stock-quote/">SSNT</a>) shares are diving close to 23% on <a href="https://ca.finance.yahoo.com/news/insider-sale-ceo-mark-meller-070316512.html">a CEO stock sale</a>.</li>



<li>Sobr Safe (NASDAQ:<a href="https://investorplace.com/stock-quotes/sobr-stock-quote/">SOBR</a>) stock is pulling back over 21% <a href="https://investorplace.com/2024/06/why-is-sobr-safe-sobr-stock-up-83-today/">after yesterday&rsquo;s rally</a>.</li>



<li>Golden Heaven (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdhg-stock-quote/">GDHG</a>) shares are tumbling more than 18% without any clear news this morning.</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/06/why-is-fresh2-group-fres-stock-up-31-today/">after climbing higher yesterday</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) shares are sliding more than 14% despite a lack of news today.</li>



<li>Vast Renewables (NASDAQ:<a href="https://investorplace.com/stock-quotes/vste-stock-quote/">VSTE</a>) stock is dropping over 14% today.</li>



<li>ThredUp (NASDAQ:<a href="https://investorplace.com/stock-quotes/tdup-stock-quote/">TDUP</a>) shares are falling more than 12% on Wednesday.</li>



<li>ThermoGenesis (NASDAQ:<a href="https://investorplace.com/stock-quotes/thmo-stock-quote/">THMO</a>) stock is decreasing over 12% on an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318372198&amp;type=PDF&amp;symbol=THMO&amp;cdn=06c6f2748734640b337b89e0d63957b3&amp;companyName=ThermoGenesis+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-04">updated agreement with CBR Systems</a>.</li>



<li>MingZhu Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ygmz-stock-quote/">YGMZ</a>) shares close out our pre-market stock movers down more than 12% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-5th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday morning as we check out all of the hottest news to start the day with!



Moving stocks this morning a partnerships, a public offering, clinical trial news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rocketing more than 123% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring over 75% with strong early morning trading.</li>



<li>Hoth Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/hoth-stock-quote/">HOTH</a>) stock is surging more than 45% <a href="https://www.nasdaq.com/press-release/hoth-therapeutics-partners-lts-therapy-systems-accelerate-novel-alzheimers-treatment">on a new partnership</a> to develop its Alzheimer&rsquo;s treatment.</li>



<li>Allarity Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/allr-stock-quote/">ALLR</a>) shares are increasing over 44% after encouraging investors to <a href="https://finance.yahoo.com/news/allarity-encourages-shareholders-vote-reverse-100000785.html">vote for a reverse stock split</a>.</li>



<li>Regencell Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/rgc-stock-quote/">RGC</a>) stock is heading more than 33% higher alongside strong pre-market trading.</li>



<li>Pieris Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/pirs-stock-quote/">PIRS</a>) shares are rising over 28% after <a href="https://www.nasdaq.com/press-release/palvella-therapeutics-and-pieris-pharmaceuticals-announce-definitive-merger-agreement">announcing a merger agreement</a>.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) stock is jumping more than 23% with heavy early morning trading today.</li>



<li>NewGenIvf (NASDAQ:<a href="https://investorplace.com/stock-quotes/nivf-stock-quote/">NIVF</a>) shares are climbing over 22% after providing a <a href="https://www.nasdaq.com/press-release/newgenivf-provides-update-potential-reverse-merger-covirix-2024-07-23">reverse merger update</a>.</li>



<li>Perfect Moment (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pmnt-stock-quote/">PMNT</a>) stock is getting a close to 19% boost after announcing a <a href="https://www.nasdaq.com/press-release/perfect-moment-teams-quiet-platforms-establish-distribution-center-us-2024-07-22">distribution center agreement</a>.</li>



<li>Catheter Precision (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vtak-stock-quote/">VTAK</a>) shares are up more than 16% without any clear news this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Azitra&nbsp;(NYSEMKT:<a href="https://investorplace.com/stock-quotes/aztr-stock-quote/">AZTR</a>) stock is crashing over 73% but only <a href="https://investorplace.com/2024/07/why-is-azitra-aztr-stock-up-315-today/">after a massive rally yesterday</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are plummeting 28% on <a href="https://www.12newsnow.com/article/news/local/texas/conns-reportedly-planning-mass-closures/502-4db60564-6fdd-4ffa-ae26-899bec91f75c">reports of impending store closures</a>.</li>



<li>ATI Physical Therapy (NYSE:<a href="https://investorplace.com/stock-quotes/atip-stock-quote/">ATIP</a>) stock is diving more than 25% without any obvious news this morning.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are tumbling over 25% on a <a href="https://finance.yahoo.com/news/verastem-oncology-announces-proposed-public-200500583.html">proposed public offering</a>.</li>



<li>Agape ATP (NASDAQ:<a href="https://investorplace.com/stock-quotes/atpc-stock-quote/">ATPC</a>) stock is taking an almost 24% beating after a rally yesterday.</li>



<li>AtlasClear (NYSEMKT:<a href="https://investorplace.com/stock-quotes/atch-stock-quote/">ATCH</a>) shares are sliding more than 22% despite a lack of news on Wednesday.</li>



<li>Sage Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/sage-stock-quote/">SAGE</a>) stock is dropping over 22% after reporting <a href="https://www.nasdaq.com/press-release/sage-therapeutics-and-biogen-announce-topline-results-phase-2-kinetic-2-study-sage">Phase 2 topline results</a>.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) shares are decreasing more than 21% <a href="https://www.nasdaq.com/press-release/volato-updates-fractional-program-additional-differentiated-benefits-2024-07-23">after a recent rally</a>.</li>



<li>Chijet Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/cjet-stock-quote/">CJET</a>) stock is slipping over 19% following yesterday&rsquo;s rally.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) shares close out our pre-market stock movers down more than 19% after a rally yesterday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Bone Biologics to raise $2.1M through exercise of warrants

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We have all of the biggest pre-market stock movers that traders need to know about on Friday morning!



Moving stocks this morning and more earnings reports, an acquisition deal, liquidation news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Iteris (NASDAQ:<a href="https://investorplace.com/stock-quotes/iti-stock-quote/">ITI</a>) stock is rocketing more than 62% <a href="https://www.nasdaq.com/press-release/iteris-be-acquired-almaviva-335-million-2024-08-09">alongside an acquisition deal</a>.</li>



<li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) shares are soaring over 61% on a <a href="https://www.nasdaq.com/press-release/nauticus-robotics-enters-aquanaut-mark-2-testing-partnership-fau-2024-08-08">new testing partnership</a>.</li>



<li>FSD Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/huge-stock-quote/">HUGE</a>) stock is surging more than 37% alongside heavy pre-market trading.</li>



<li>Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) shares are gaining over 30% with the <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318504957&amp;type=PDF&amp;symbol=BBLG&amp;cdn=81b72413280ee9face7494c21cc37055&amp;companyName=Bone+Biologics+Corp&amp;formType=ARS&amp;formDescription=Annual+Report+to+Security+Holders&amp;dateFiled=2024-08-08">release of its annual report</a>.</li>



<li>Pitney Bowes (NYSE:<a href="https://investorplace.com/stock-quotes/pbi-stock-quote/">PBI</a>) stock is rising more than 30% on plans to <a href="https://finance.yahoo.com/news/pitney-bowes-liquidate-ecommerce-unit-221312483.html">liquidate its e-commerce unit</a>.</li>



<li>Marin Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrin-stock-quote/">MRIN</a>) shares are increasing over 28% after <a href="https://www.businesswire.com/news/home/20240808458407/en/Marin-Software-Extends-Reach-with-Reddit-and-X-Support">adding support for Reddit and X</a>, previously called Twitter.</li>



<li>Clearmind Medicine (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmnd-stock-quote/">CMND</a>) stock is heading more than 27% higher without any clear news this morning.</li>



<li>Doximity (NYSE:<a href="https://investorplace.com/stock-quotes/docs-stock-quote/">DOCS</a>) shares are climbing over 27% on a <a href="https://www.marketwatch.com/story/doximity-shares-rally-after-beating-1q-earnings-guidance-expectations-b9ce97d7?mod=markets">fiscal Q1 earnings beat</a>.</li>



<li>Satellogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/satl-stock-quote/">SATL</a>) stock is jumping more than 26% today.</li>



<li>Babcock &amp; Wilcox (NYSE:<a href="https://investorplace.com/stock-quotes/bw-stock-quote/">BW</a>) shares are up over 25% after releasing its <a href="https://www.businesswire.com/news/home/20240808728017/en/Babcock-Wilcox-Enterprises-Reports-Second-Quarter-2024-Results-Earnings-Growth-Driven-By-Strong-Operating-Performance">Q2 earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>AN2 Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/antx-stock-quote/">ANTX</a>) stock is diving more than 33% <a href="https://www.nasdaq.com/press-release/an2-therapeutics-provides-update-ebo-301-phase-2-3-study-evaluating-epetraborole">with a clinical trial update</a>.</li>



<li>American Vanguard (NYSE:<a href="https://investorplace.com/stock-quotes/avd-stock-quote/">AVD</a>) shares are tumbling over 29% with the <a href="https://www.nasdaq.com/press-release/american-vanguard-reports-q2-2024-results-2024-08-08">release of its latest earnings report</a>.</li>



<li>PubMatic (NASDAQ:<a href="https://investorplace.com/stock-quotes/pubm-stock-quote/">PUBM</a>) stock is taking a more than 27% beating on <a href="https://www.stocktitan.net/news/PUBM/pub-matic-announces-second-quarter-2024-financial-zmrbbq0dmfh8.html">missed Q2 revenue</a>.</li>



<li>Eventbrite (NYSE:<a href="https://investorplace.com/stock-quotes/eb-stock-quote/">EB</a>) shares are sliding over 23% alongside <a href="https://www.tipranks.com/news/company-announcements/eventbrite-announces-layoffs-and-welcomes-new-coo-cfo">layoffs and leadership changes</a>.</li>



<li>Beauty Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/skin-stock-quote/">SKIN</a>) stock is decreasing more than 22% after <a href="https://www.nasdaq.com/press-release/beautyhealth-reports-second-quarter-2024-financial-results-2024-08-08">posting its Q2 earnings report</a>.</li>



<li>Cutera (NASDAQ:<a href="https://investorplace.com/stock-quotes/cutr-stock-quote/">CUTR</a>) shares are dropping over 21% with its <a href="https://www.nasdaq.com/press-release/cuterar-announces-second-quarter-2024-financial-results-2024-08-08">latest earnings news</a>.</li>



<li>Microvast (NASDAQ:<a href="https://investorplace.com/stock-quotes/mvst-stock-quote/">MVST</a>) stock is falling more than 19% after releasing its <a href="https://ir.microvast.com/static-files/b376f438-a4e5-4a1a-ac22-a6107e450b24">Q2 2024 earnings</a>.</li>



<li>FiscalNote (NYSE:<a href="https://investorplace.com/stock-quotes/note-stock-quote/">NOTE</a>) shares are slipping over 18% after <a href="https://finance.yahoo.com/news/fiscalnote-holdings-inc-note-reports-231505554.html">posting a Q2 loss</a>.</li>



<li>Nerdy (NYSE:<a href="https://investorplace.com/stock-quotes/nrdy-stock-quote/">NRDY</a>) stock is dipping more than 18% after <a href="https://www.nasdaq.com/press-release/nerdy-announces-second-quarter-2024-financial-results-2024-08-08">releasing its Q2 earnings report</a>.</li>



<li>Five9 (NASDAQ:<a href="https://investorplace.com/stock-quotes/fivn-stock-quote/">FIVN</a>) shares close out our pre-market stock movers down over 15% with its <a href="https://www.nasdaq.com/press-release/five9-surpasses-1-billion-annual-revenue-run-rate-2024-08-08">most recent earnings report</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-9th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bblg-stock-quote/">BBLG</a>) just reported results for the second quarter of 2024.<ul><li>Bone Biologics reported earnings per share of -67 cents. This was above the analyst estimate for EPS of -$1.39.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bblg-stock-earnings-bone-biologics-for-q2-of-2024/">BBLG Stock Earnings: Bone Biologics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BBLG Stock Earnings: Bone Biologics Beats EPS for Q2 2024

ALLR

ANTX

ARQT

ASNS

ATCH

ATIP

ATPC

AZTR

BBLG

CAPR

CJET

CLDI

CMND

CONN

CUTR

DOCS

DRMA

FIVN

FRES

GDHG

HOTH

HSCS

HUGE

KITT

LSDI

MITQ

MLGO

MRIN

MVST

NDRA

NEPH

NIVF

NOTE

NRDY

NTBL

NUZE

NVAX

PIRS

PMNT

PUBM

SAGE

SATL

SFIX

SKIN

SLRX

SOAR

SOBR

SSNT

TDUP

THMO

UCAR

VSTE

VSTM

VTAK

WKME

YGMZ

Press Releases

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

Bone Biologics Reports Progress With NB1 Clinical Program

Bone Biologics Announces Pricing of $2.0 Million Public Offering

Bone Biologics Announces Closing of $2.0 Million Public Offering

Bone Biologics Executives to be Interviewed in a "CEO Chat" by Zacks Small-Cap Research Analyst on June 20th

First Two Patients Treated in Pilot Clinical Study with Bone Biologics' NB1 Bone Graft Device in Spine Fusion

Actinium Pharmaceuticals (ATNM) Unveils Promising Advances in Targeted Radiotherapies for Cancer Treatment

Bone Biologics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Comments

Bone Biologics

Noticias

Últimas noticias sobre Bone Biologics (NASDAQ:BBLG) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL